{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:59:50Z","timestamp":1761469190677,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.transci.2023.103829","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T06:56:33Z","timestamp":1696920993000},"page":"103829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacoeconomic issues in stem cell mobilization"],"prefix":"10.1016","volume":"62","author":[{"given":"Carlo","family":"Lazzaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2023.103829_bib1","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/sj.bmt.1700867","article-title":"Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSFalone","volume":"20","author":"Alegre","year":"1997","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103829_bib2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1046\/j.1365-2141.1997.2783095.x","article-title":"Factors influencing collection of peripheral blood progenitor cell following high-dose cyclophosphamide and granulocyte colonystimulating factor in patients with multiple myeloma","volume":"98","author":"Goldschmidt","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2023.103829_bib3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/bmt.2014.39","article-title":"Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European group for blood and marrow transplantation","volume":"49","author":"Mohty","year":"2014","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103829_bib4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000070967","article-title":"Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cell in patients with multiple myeloma","volume":"109","author":"Petrucci","year":"2003","journal-title":"Acta Haematol"},{"key":"10.1016\/j.transci.2023.103829_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.transci.2012.03.004","article-title":"Who should be really considered as a poor mobilizer in the plerixafor era?","volume":"47","author":"Andreola","year":"2012","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.transci.2023.103829_bib6","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and GCSF to mobilize hematopoietic stem cell for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2023.103829_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/trf.12265","article-title":"Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma","volume":"54","author":"Lanza","year":"2014","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2023.103829_bib8","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1517\/14712598.2015.971750","article-title":"Plerixafor: what we still have to learn","volume":"15","author":"Lanza","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.transci.2023.103829_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/bmt.2014.196","article-title":"Plerixafor in patients with lymphoma and multiple myeloma: effectiveness in cases with very low circulating CD34+ cell levels and preemptive intervention vs remobilization","volume":"50","author":"Sanchez-Ortega","year":"2015","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2023.103829_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2014.79","article-title":"Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients","volume":"4","author":"Clark","year":"2014","journal-title":"Blood Cancer J"},{"year":"2015","series-title":"Methods for the economic evaluation of health care programmes","author":"Drummond","key":"10.1016\/j.transci.2023.103829_bib11"},{"year":"2016","series-title":"Cost-effectiveness in health and medicine","key":"10.1016\/j.transci.2023.103829_bib12"},{"issue":"7219","key":"10.1016\/j.transci.2023.103829_bib13","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/bmj.319.7219.1258","article-title":"Tragic choices in health care: lessons from the child B case","volume":"319","author":"Ham","year":"1999","journal-title":"BMJ"},{"year":"2006","series-title":"Decision modelling for health economic evaluation","author":"Briggs","key":"10.1016\/j.transci.2023.103829_bib14"},{"key":"10.1016\/j.transci.2023.103829_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1478-7547-4-14","article-title":"Priority setting of health interventions: the need for multi-criteria decision analysis","volume":"4","author":"Baltussen","year":"2006","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.transci.2023.103829_bib16","series-title":"Distributional cost-effectiveness analysis","first-page":"44","article-title":"Designing a distributuional cost-effectiveness analysis","author":"Cookson","year":"2021"},{"issue":"2 Suppl","key":"10.1016\/j.transci.2023.103829_bib17","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1177\/0272989X98018002S09","article-title":"Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis","volume":"18","author":"Stinnett","year":"1998","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.transci.2023.103829_bib18","series-title":"Economic evaluation in health care: merging theory with practice","first-page":"172","article-title":"Handling uncertainty in economic evaluation and presenting the results","author":"Briggs","year":"2001"},{"issue":"2","key":"10.1016\/j.transci.2023.103829_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3020","article-title":"Handling uncertainty when performing economic evaluation of healthcare interventions","volume":"3","author":"Briggs","year":"1999","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.transci.2023.103829_bib20","series-title":"New York (NY)","article-title":"An introduction to the bootstrap","author":"Efron","year":"1993"},{"key":"10.1016\/j.transci.2023.103829_bib21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1146\/annurev.publhealth.23.100901.140534","article-title":"Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies","volume":"23","author":"Briggs","year":"2002","journal-title":"Annu Rev Public Health"},{"issue":"8","key":"10.1016\/j.transci.2023.103829_bib22","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hec.635","article-title":"Representing uncertainty: the role of cost-effectiveness acceptability curves","volume":"10","author":"Fenwick","year":"2001","journal-title":"Health Econ"},{"year":"2022","series-title":"Principles of Biostatistics","author":"Pagano","key":"10.1016\/j.transci.2023.103829_bib23"},{"issue":"7","key":"10.1016\/j.transci.2023.103829_bib24","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/eurheartj\/ehi809","article-title":"Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk","volume":"27","author":"Deckers","year":"2006","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.transci.2023.103829_bib25","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/hrt.2005.086728","article-title":"EUROPA trial investigators. cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study","volume":"93","author":"Briggs","year":"2007","journal-title":"Heart"},{"issue":"3","key":"10.1016\/j.transci.2023.103829_bib26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0899-3467(07)60142-6","article-title":"Writing narrative literature reviews for peer-reviewed journals: secrets of the trade","volume":"5","author":"Green","year":"2006","journal-title":"J Chiropr Med"},{"issue":"7","key":"10.1016\/j.transci.2023.103829_bib27","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.hlc.2018.03.027","article-title":"An introduction to writing narrative and systematic reviews - tasks, tips and traps for aspiring authors","volume":"27","author":"Gregory","year":"2018","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.transci.2023.103829_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.936171","article-title":"What is known about neuroplacentology in fetal growth restriction and in preterm infants: a narrative review of literature","volume":"13","author":"Gardella","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.transci.2023.103829_bib29","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.transci.2023.103829_bib30","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s10198-021-01426-6","article-title":"CHEERS 2022 ISPOR good research practices task force. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"23","author":"Husereau","year":"2022","journal-title":"Eur J Health Econ"},{"issue":"1","key":"10.1016\/j.transci.2023.103829_bib31","first-page":"33","article-title":"Economic evaluation of plerixafor for stem cell mobilization","volume":"18","author":"Kymes","year":"2012","journal-title":"Am J Manag Care"},{"issue":"6","key":"10.1016\/j.transci.2023.103829_bib32","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/jca.21290","article-title":"Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients","volume":"28","author":"Tichop\u00e1d","year":"2013","journal-title":"J Clin Apher"},{"issue":"2","key":"10.1016\/j.transci.2023.103829_bib33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/1078155213484785","article-title":"GCSF with or without chemotherapy compared to Plerixafor with GCSF as salvage mobilization regimen in patients with multiple myeloma and lymphoma: collection effectiveness and cost effectiveness analysis","volume":"20","author":"Abdel-Rahman","year":"2014","journal-title":"J Oncol Pharm Pr"},{"issue":"5","key":"10.1016\/j.transci.2023.103829_bib34","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jca.21433","article-title":"Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial","volume":"31","author":"Martin","year":"2016","journal-title":"J Clin Apher"},{"issue":"8","key":"10.1016\/j.transci.2023.103829_bib35","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1038\/s41409-021-01251-8","article-title":"Chemotherapy-based versus chemotherapy-free stem cell mobilization (\u00b1 plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis","volume":"56","author":"Lazzaro","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"10.1016\/j.transci.2023.103829_bib36","article-title":"A consensus-based checklist for the critical appraisal of cost-of-illness (COI) studies","volume":"39","author":"Schnitzler","year":"2023","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.transci.2023.103829_bib37","series-title":"Economic evaluation in health care: merging theory with practice","first-page":"68","article-title":"Costing in economic evaluations","author":"Brouwer","year":"2001"},{"year":"1996","series-title":"Rationing in the NHS. Principles & pragmatism","author":"New","key":"10.1016\/j.transci.2023.103829_bib38"},{"issue":"7","key":"10.1016\/j.transci.2023.103829_bib39","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/00005650-199407000-00003","article-title":"The willingness to pay for in vitro fertilization: a pilot study using contingent valuation","volume":"32","author":"Neumann","year":"1994","journal-title":"Med Care"},{"key":"10.1016\/j.transci.2023.103829_bib40","series-title":"A cost-benefit analysis of in-vitro fertilisation in Italy","article-title":"Measuring public value","author":"Fattore","year":"2009"},{"issue":"4","key":"10.1016\/j.transci.2023.103829_bib41","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/027298902400448867","article-title":"Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease","volume":"22","author":"Briggs","year":"2002","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.transci.2023.103829_bib42","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1472-6963-6-68","article-title":"Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of \"community acquired\" syncope","volume":"6","author":"Hoch","year":"2006","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"10.1016\/j.transci.2023.103829_bib43","first-page":"91","volume":"18","author":"Lazzaro","year":"2010","journal-title":"Infez Med"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223002446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050223002446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:56:33Z","timestamp":1761468993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050223002446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1473050223002446"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2023.103829","relation":{},"ISSN":["1473-0502"],"issn-type":[{"type":"print","value":"1473-0502"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacoeconomic issues in stem cell mobilization","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2023.103829","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103829"}}